Epidemiology

You have full text access to this OnlineOpen article

Ascertainment and diagnostic accuracy for hematopoietic lymphoproliferative malignancies in Sweden 1964–2003

  1. Ingemar Turesson1,†,*,
  2. Martha S. Linet2,
  3. Magnus Björkholm3,
  4. Sigurdur Y. Kristinsson3,
  5. Lynn R. Goldin2,
  6. Neil E. Caporaso2,
  7. Ola Landgren2,3

Article first published online: 21 JUN 2007

DOI: 10.1002/ijc.22912

Issue

International Journal of Cancer

International Journal of Cancer

Volume 121, Issue 10, pages 2260–2266, 15 November 2007

Additional Information

How to Cite

Turesson, I., Linet, M. S., Björkholm, M., Kristinsson, S. Y., Goldin, L. R., Caporaso, N. E. and Landgren, O. (2007), Ascertainment and diagnostic accuracy for hematopoietic lymphoproliferative malignancies in Sweden 1964–2003. Int. J. Cancer, 121: 2260–2266. doi: 10.1002/ijc.22912

Author Information

  1. 1

    Section of Hematology, Department of Medicine, Malmö University Hospital, University of Lund, Malmö, Sweden

  2. 2

    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD

  3. 3

    Division of Medicine, Hematology Center, Karolinska Institute and University Hospital, Stockholm, Sweden

  1. †

    Fax: +46-4033-6281.

*Section of Hematology, Department of Medicine, Malmö Universit Hospital, SE-205 02 Malmö, Sweden

Publication History

  1. Issue published online: 25 SEP 2007
  2. Article first published online: 21 JUN 2007
  3. Manuscript Accepted: 2 MAY 2007
  4. Manuscript Received: 19 MAR 2007

Funded by

  • Section of Hematology, Department of Medicine, Malmö University Hospital, Malmö, Sweden
  • Swedish Cancer Society
  • Stockholm County Council
  • Karolinska Institutet Foundations
  • the Intramural Research Program of the National Cancer Institute, National Institutes of Health

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (99K)

REFERENCES

  • 1
    Mattsson B, Wallgren A. Completeness of the Swedish Cancer Register. Non-notified cancer cases recorded on death certificates in 1978. Acta Radiol Oncol 1984; 23: 305–13.
  • 2
    Astrom M, Bodin L, Tidefelt U. Adjustment of incidence rates after an estimate of completeness and accuracy in registration of acute leukemias in a Swedish population. Leuk Lymphoma 2001; 41: 559–70.
  • 3
    Hilsenbeck SG, Kurucz C, Duncan RC. Estimation of completeness and adjustment of age-specific and age-standardized incidence rates. Biometrics 1992; 48: 1249–62.
  • 4
    Teppo L, Pukkala E, Lehtonen M. Data quality and quality control of a population-based cancer registry. Experience in Finland. Acta Oncol 1994; 33: 365–9.
  • 5
    Hemminki K, Li X, Plna K, Granstrom C, Vaittinen P. The nation-wide Swedish family-cancer database—updated structure and familial rates. Acta Oncol 2001; 40: 772–7.
  • 6
    Hemminki K, Vaittinen P. National database of familial cancer in Sweden. Genet Epidemiol 1998; 15: 225–36.
    Direct Link:
  • 7
    Goldin LR, Pfeiffer RM, Gridley G, Gail MH, Li X, Mellemkjaer L, Olsen JH, Hemminki K, Linet MS. Familial aggregation of Hodgkin lymphoma and related tumors. Cancer 2004; 100: 1902–8.
    Direct Link:
  • 8
    Goldin LR, Pfeiffer RM, Li X, Hemminki K. Familial risk of lymphoproliferative tumors in families of patients with chronic lymphocytic leukemia: results from the Swedish Family-Cancer Database. Blood 2004; 104: 1850–4.
  • 9
    Goldin LR, Landgren O, McMaster ML, Gridley G, Hemminki K, Li X, Mellemkjaer L, Olsen JH, Linet MS. Familial aggregation and heterogeneity of non-Hodgkin lymphoma in population-based samples. Cancer Epidemiol Biomarkers Prev 2005; 14: 2402–6.
  • 10
    Landgren O, Linet MS, McMaster ML, Gridley G, Hemminki K, Goldin LR. Familial characteristics of autoimmune and hematologic disorders in 8,406 multiple myeloma patients: a population-based case-control study. Int J Cancer 2006; 118: 3095–8.
    Direct Link:
  • 11
    Landgren O, Engels EA, Caporaso NE, Gridley G, Mellemkjaer L, Hemminki K, Linet MS, Goldin LR. Patterns of autoimmunity and subsequent chronic lymphocytic leukemia in Nordic countries. Blood 2006; 108: 292–6.
  • 12
    Landgren O, Engels EA, Pfeiffer RM, Gridley G, Mellemkjaer L, Olsen JH, Kerstann KF, Wheeler W, Hemminki K, Linet MS, Goldin LR. Autoimmunity and susceptibility to Hodgkin lymphoma: a population-based case-control study in Scandinavia. J Natl Cancer Inst 2006; 98: 1321–30.
  • 13
    Khorram-Manesh A, Jansson S, Wangberg B, Nilsson O, Tisell LE, Ahlman H. Mortality associated with pheochromocytoma: increased risk for additional tumors. Ann NY Acad Sci 2006; 1073: 444–8.
    Direct Link:
  • 14
    Lambe M, Hsieh C, Trichopoulos D, Ekbom A, Pavia M, Adami HO. Transient increase in the risk of breast cancer after giving birth. N Engl J Med 1994; 331: 5–9.
  • 15
    Tulinius H, Storm HH, Pukkala E, Andersen A, Ericsson J. Cancer in the Nordic countries, 1981–86. A joint publication of the five Nordic Cancer Registries. APMIS Suppl 1992; 31: 1–194.
  • 16
    Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A, Hemminki K. Environmental and heritable factors in the causation of cancer—analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000; 343: 78–85.
  • 17
    Hartman M, Czene K, Reilly M, Bergh J, Lagiou P, Trichopoulos D, Adami HO, Hall P. Genetic implications of bilateral breast cancer: a population based cohort study. Lancet Oncol 2005; 6: 377–82.
  • 18
    Winther JF, Sankila R, Boice JD, Tulinius H, Bautz A, Barlow L, Glattre E, Langmark F, Moller TR, Mulvihill JJ, Olafsdottir GH, Ritvanen A, et al. Cancer in siblings of children with cancer in the Nordic countries: a population-based cohort study. Lancet 2001; 358: 711–7.
  • 19
    Bergfeldt K, Rydh B, Granath F, Gronberg H, Thalib L, Adami HO, Hall P. Risk of ovarian cancer in breast-cancer patients with a family history of breast or ovarian cancer: a population-based cohort study. Lancet 2002; 360: 891–4.
  • 20
    Travis LB, Curtis RE, Glimelius B, Holowaty E, Van Leeuwen FE, Lynch CF, Adami J, Gospodarowicz M, Wacholder S, Inskip P, et al. Second cancers among long-term survivors of non-Hodgkin's lymphoma. J Natl Cancer Inst 1993; 85: 1932–7.
  • 21
    Travis LB, Hauptmann M, Gaul LK, Storm HH, Goldman MB, Nyberg U, Berger E, Janower ML, Hall P, Monson RR, Holm LE, Land CE, et al. Site-specific cancer incidence and mortality after cerebral angiography with radioactive thorotrast. Radiat Res 2003; 160: 691–706.
  • 22
    Travis LB, Hill D, Dores GM, Gospodarowicz M, van Leeuwen FE, Holowaty E, Glimelius B, Andersson M, Pukkala E, Lynch CF, Pee D, Smith SA, et al. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst 2005; 97: 1428–37.
  • 23
    Jaffe ES, Harris NL, Stein H, Vardiman JW. World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press, 2001.
  • 24
    Stansfeld AG, Diebold J, Noel H, Kapanci Y, Rilke F, Kelenyi G, Sundstrom C, Lennert K, van Unnik JA, Mioduszewska O, et al. Updated Kiel classification for lymphomas. Lancet 1988; 1: 292–3.
  • 25
    Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J. Lymphoma classification—from controversy to consensus: the R.E.A.L. and WHO classification of lymphoid neoplasms. Ann Oncol 2000; 11 ( Suppl 1): 3–10.
  • 26
    Anonymous. Patientregistret 1987–1996: Kvalitet och innehåll (Swedish). EpC, National Board of Health and Welfare, 1998.
  • 27
    Martinsson U, Glimelius B, Sundstrom C. Lymphoma incidence in a Swedish county during 1969–1987. Acta Oncol 1992; 31: 275–82.
  • 28
    Middleton RJ, Gavin AT, Reid JS, O'Reilly D. Accuracy of hospital discharge data for cancer registration and epidemiological research in Northern Ireland. Cancer Causes Control 2000; 11: 899–905.
  • 29
    Bullard J, Coleman MP, Robinson D, Lutz JM, Bell J, Peto J. Completeness of cancer registration: a new method for routine use. Br J Cancer 2000; 82: 1111–6.
  • 30
    Phekoo K, Moller H, Richards M, Schey S. Comparison of a specialist haematological malignancy database against a regional cancer registry: case ascertainment and diagnostic accuracy. Br J Haematol 2002; 119: 697–705.
    Direct Link:
  • 31
    Skjelbakken T, Lochen ML, Dahl IM. Haematological malignancies in a general population, based on information collected from a population study, hospital records, and the Cancer Registry of Norway: the Tromso Study. Eur J Haematol 2002; 69: 67–75.
    Direct Link:
  • 32
    Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46: 219–34.
  • 33
    Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J, Vaugier G, Potron G, Colona P, Oberling F, Thomas M, Tchernia G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981; 48: 198–206.
    Direct Link:
  • 34
    Owen RG, Treon SP, Al-Katib A, Fonseca R, Greipp PR, McMaster ML, Morra E, Pangalis GA, San Miguel JF, Branagan AR, Dimopoulos MA. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003; 30: 110–15.
  • 35
    Anonymous. Chronic lymphocytic leukemia: recommendations for diagnosis, staging, and response criteria. International Workshop on Chronic Lymphocytic Leukemia. Ann Intern Med 1989; 110: 236–8.
  • 36
    Anonymous. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003; 121: 749–57.
    Direct Link:
View Full Article (HTML) Get PDF (99K)